Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study will evaluate the safety, tolerability and exposure of repeat escalating oral doses, a loading dose/maintenance dose regimen of GSK580416 and when co administered with ketoconazole, a PGP/CYP3A4 inhibitor.
A three part study in healthy adult subjects to evaluate the safety, tolerability and pharmacokinetics of repeat escalating oral doses of GSK580416; the safety, tolerability, and pharmacokinetics of GSK580416 following a loading dose regimen; and the effect of ketoconazole on the pharmacokinetics of GSK580416
A Three Part Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeat Escalating Oral Doses of GSK580416; the Safety, Tolerability, and Pharmacokinetics of GSK580416 Following a Loading Dose Regimen; and the Effect of Ketoconazole on the Pharmacokinetics of GSK580416
Study Start Date
Primary Completion Date
Study Completion Date
Resource links provided by the National Library of Medicine
Safety and tolerability of GSK580416 doses determined from clinical safety and tolerability data from all adverse event reporting, 12-lead ECGs, vital signs, nursing/physician observation, and safety laboratory tests
Secondary Outcome Measures
Pharmacokinetics of GSK580416 as determined by AUC, Cmax, tmax, half-life, and Ct.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 64 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy adults (as determined by medical evaluation including history, physical exam, vital signs, laboratory tests, and cardiac monitoring)
Aged 18-60yrs, with BMI of 19-31kg/m2.
Females must be of non-childbearing potential.
QTc < 450 msec at screening.
Subjects must be able to give consent and comply with restrictions of study.
Clinically significant CNS, cardiac, pulmonary, metabolic, renal, hepatic or GI condition or history that may place the subject at an unacceptable risk or may interfere with absorption, distribution, metabolism, or excretion of drug.
Positive urine drug screen.
Positive urine test for alcohol.
Positive HIV or Hep B and/or C assay.
History of regular tobacco use within 3 monts prior to screening or cotinine levels indicative of smoking at screening.
History of regular alcohol consumption (14 units/week for women and 21 units/week for men).
History of drug abuse or dependence within 12 months of study.
Participation in another drug trial within 30 days of first dose.
Exposure to more than 4 new chemical entities within 12 months of first dose.
Use of prescription and non-prescription drugs including vitamins, dietary supplements, herbals within 7 days of first dose or St. John's Wort within 28 days of the first dose.
Consumption of red wine, Seville oranges, grapefruit, or grapefruit juices within 14 days of first dose.
Donation of blood in excess of 500 mL within 56 days of dosing. No blood donation is allowed 30 days prior to study participation.
A positive immunochemical fecal occult blood test at screening.
History of sensitivity to any of the study medications.
History of sensitivity to heparin or heparin-induced thrombocytopenia.
History of orthostatic hypotension or orthostatic hypotension at screening.